Lexeo Therapeutics Scores Positive Early Data For APOE4-Alzheimers Gene Therapy
Lexeo therapeutics' gene therapy for alzheimer's has shown that it can reduce biomarkers of the disease in a small study, including reductions in disease biomarkers. A phase i/ii study of lexeo therapeutics’ gene therapy to treat patients with alzheimer’s associated with the apoe4 genetic variant has achieved good interim results. (lxeo) wednesday reported positive interim results from the phase 1/2 study of its gene therapy candidate lx1001 for the. “initial data have shown meaningful apoe2 target engagement and declines in cerebrospinal fluid biomarkers, which support our belief that lx1001 has therapeutic potential. Lexeo therapeutics has announced positive initial data from its phase i/ii trial of lx1001, a gene therapy intended for the treatment of apoe4 homozygous alzheimer’s.